aap Implantate Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 5/20/2026)
| Balance Sheet | Total Assets | 13,751,000.00 | ROE | 63.23 % |
| Balance Sheet | Total Equity | 8,695,000.00 | ROA | -18.80 % |
| Cashflow | Capital Expenditures | -725,000.00 | P/FCF | -9.21 |
| Cashflow | Free Cash Flow | -2,159,000.00 | – | – |
| Cashflow | Operating Cash Flow | -1,434,000.00 | P/CF | -13.87 |
| Income | Earnings per Share (diluted) | -0.19 | Div. Yield | – |
| Income | Net Income | -2,585,000.00 | P/E | -7.53 |
| Income | Shares Outstanding | 13,909,408.00 | P/B | 2.29 |
| Income | Total Revenue | 12,487,000.00 | P/S | 1.59 |
Ratios calculated on: 10/14/2026
Company Description
aap Implantate AG, a medical device company, develops, manufactures, and markets trauma products for orthopedics in Germany, the United States, and internationally. It offers LOQTEQ, an anatomical plating system for fracture treatment; and a range of cannulated screws, standard plates, and screws. The company sells its products directly to hospitals, buying syndicates, and hospital groups, as well as through a network of distributors under the aap brand name. aap Implantate AG was founded in 1990 and is headquartered in Berlin, Germany.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.aap.de
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more